We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Merus (MRUS – Research Report) yesterday and set a price target of ...

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to ...

Merus (NASDAQ:MRUS – Get Free Report) had its price target hoisted by research analysts at Citigroup from $89.00 to $97.00 in ...

Analyst Ami Fadia of Needham maintained a Buy rating on Merus (MRUS – Research Report), retaining the price target of $85.00.Pick the best ...

Needham & Company LLC reaffirmed their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a report published on Monday,Benzinga reports. The firm currently has a $85.00 price target on the ...

Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or ...

In trading on Monday, shares of Merus NV (Symbol: MRUS) entered into oversold territory, hitting an RSI reading of 29.5, after changing hands as low as $44.16 per share. By comparison, the current ...

Merus partners with Partner Therapeutics for U.S. rights to Zeno in NRG1+ cancer. Updated petosemtamab data emerge as a key ...

Team Rebounds: 1. Team Turnovers: 1. Blocked Shots: 6 (Anderson, Gonzalez, Linhardt, Mims, Mrus). Turnovers: 15 (Anderson 2, Linhardt 2, Payne 2, Steele 2, Yearout 2, Brickner, Gonzalez, Klapper, ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology ...

On Wednesday, the FDA approved Merus N.V.’s (NASDAQ:MRUS) Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell ...